UPDATE: J.P. Morgan Initiates Coverage MedAssets on Good Market Position

In a report published Monday, J.P. Morgan analyst Gavin Weiss initiated coverage on MedAssets (NASDAQ: MDAS ) with a Neutral rating and $23.00 price target. In the report, J.P. Morgan noted, “While we like the company's positioning in both the revenue cycle and group purchasing markets, we are concerned about